Leerink Partners analyst Mike Kratky maintained a Buy rating on AxoGen (AXGN – Research Report) on November 25 and set a price target of $0.00.

Lexicon completes patient enrollment in phase 2B PROGRESS study of LX9211 in diabetic peripheral neuropathic pain: The Woodlands, Texas Thursday, November 28, 2024, 12:00 Hrs [IST ...

Scientists examine the effectiveness of an antibody targeting cell adhesion molecule 1 in alleviating pain-induced neuronal activation. Cell surface proteins are essential for facilitating cell ...

Discover various promising treatments in development to address the unmet needs of people with Charcot–Marie–Tooth disease.